Most kidney cancers are found by accident. A CT scan or ultrasound ordered for an unrelated reason, like back pain or a routine checkup, picks up a mass on the kidney that no one was looking for. From there, diagnosis follows a structured path: imaging to characterize the mass, blood and urine tests to check kidney function, and sometimes a biopsy to confirm the type of tumor. Unlike many other cancers, kidney cancer often doesn’t require a biopsy before treatment, because imaging alone can be highly informative.
How Most Kidney Masses Are Found
Kidney cancer rarely causes symptoms in its early stages. Blood in the urine, flank pain, or a lump you can feel in your side typically show up only after the tumor has grown significantly. The majority of kidney masses are discovered incidentally during imaging for something else entirely. An abdominal ultrasound, a CT scan for stomach pain, or even a scan after a car accident can reveal a mass that turns out to be cancerous.
Once a suspicious mass appears on initial imaging, your doctor will order more detailed scans and lab work to figure out what it is, how large it is, and whether it has spread.
CT Scans and MRI: The Primary Tools
A multiphase CT scan is the most common next step. This involves taking images of the kidneys at several points before and after a contrast dye is injected into your vein. The way a mass absorbs and releases that dye over time reveals a lot about whether it’s likely cancerous. Solid masses that “light up” with contrast enhancement are more suspicious than simple fluid-filled cysts.
MRI plays a particularly important role when the mass is a complex cyst, meaning it has internal walls, thickened borders, or other features that make it hard to classify on CT alone. For these complex cystic masses, CT has limited accuracy, with only about 36% sensitivity and 76% specificity. MRI performs significantly better, reaching 71% sensitivity and 91% specificity, because it’s more sensitive at detecting subtle enhancement patterns.
A newer MRI-based tool called the Clear Cell Likelihood Score helps radiologists estimate the probability that a solid mass is the most common subtype of kidney cancer (clear cell renal cell carcinoma). The algorithm analyzes multiple MRI characteristics and assigns a score from 1 to 5. When the score is 4 or higher, it correctly identifies clear cell tumors with about 83% accuracy for smaller masses and 92% for slightly larger ones. A score of 1 is similarly useful for identifying a different, generally less aggressive subtype called papillary renal cell carcinoma, with accuracy reaching 90% or higher.
Classifying Cystic Masses
Not every kidney mass is a solid tumor. Many are cysts, and most cysts are completely harmless. Radiologists use the Bosniak classification system to sort cystic kidney masses into categories based on how they look on imaging, which directly guides whether you need treatment or just monitoring.
- Bosniak I and II: Simple or nearly simple cysts with thin walls and no concerning features. These are benign. Bosniak II cysts have a malignancy rate below 1%.
- Bosniak IIF: Slightly more complex cysts with minimally thickened walls or multiple internal dividers. The “F” stands for follow-up, because these need periodic imaging. Malignancy rates range from 0% to 38%.
- Bosniak III: Cysts with thick, irregular walls or internal structures. These are considered indeterminate, and roughly half turn out to be malignant.
- Bosniak IV: Cysts containing solid nodules that enhance with contrast dye. About 90% are cancerous.
This classification system matters because it determines what happens next. A Bosniak I cyst needs nothing. A Bosniak IV mass will almost certainly need treatment.
Blood and Urine Tests
There is no single blood test that confirms kidney cancer. Instead, a panel of blood tests helps paint a broader picture. Your doctor will check kidney function markers like creatinine, since knowing how well your kidneys work is essential before planning any imaging with contrast dye or considering surgery.
Certain blood chemistry values can be abnormal in kidney cancer. Elevated calcium, high levels of an enzyme called lactate dehydrogenase (LDH), or abnormal liver enzyme levels sometimes appear. These don’t diagnose cancer on their own, but they can support a diagnosis when combined with imaging findings and help determine how aggressive the cancer may be. A complete blood count and urinalysis (checking for blood in the urine) are also standard parts of the workup.
When a Biopsy Is Needed
Kidney cancer is unusual compared to most cancers in that a biopsy isn’t always required before treatment. If imaging clearly shows a solid, enhancing mass in a healthy patient, many surgeons will proceed directly to removing part or all of the kidney without first taking a tissue sample. The reasoning is straightforward: the imaging is convincing enough, and the patient is going to need surgery regardless of what a biopsy shows.
A biopsy is more valuable in specific situations. It’s recommended when the mass might not be a primary kidney cancer at all, for example if there’s suspicion it could be lymphoma, a metastasis from cancer elsewhere, or an infection mimicking a tumor. It’s also strongly advised before heat-based or freezing treatments (thermal ablation), since those procedures destroy the tumor in place and leave no surgical specimen for a pathologist to examine afterward.
People with significantly reduced kidney function are another group where biopsy is especially helpful. In that population, kidney masses are more likely to be benign or slow-growing, so confirming what you’re dealing with before committing to surgery can prevent unnecessary loss of kidney tissue. Similarly, biopsy is useful when the decision between removing part of the kidney versus the whole kidney is unclear, and knowing the exact tumor type would tip the balance.
Biopsy is generally avoided for purely cystic masses. The risk of tumor cells spilling outside the cyst, combined with a high chance of getting a sample that isn’t informative, makes it a poor trade-off. For older or frail patients who will be monitored conservatively no matter what the biopsy shows, the procedure adds risk without changing the plan.
How Kidney Cancer Is Staged
Once a diagnosis is made or strongly suspected, staging determines how far the cancer has progressed. The TNM system categorizes the tumor based on its size, whether it has reached nearby veins or tissues, and whether it has spread to lymph nodes or distant organs.
Tumor size thresholds are central to staging. A tumor 4 cm or smaller that’s confined to the kidney is classified as T1a, the earliest stage. Tumors between 4 and 7 cm are T1b. Once a tumor exceeds 7 cm but remains within the kidney, it moves to T2 (split into T2a for 7 to 10 cm and T2b for anything larger). These size cutoffs matter because they directly influence treatment recommendations.
T3 describes tumors that have grown into major blood vessels near the kidney or into the fat surrounding the kidney, but haven’t broken through the outer envelope of tissue (called Gerota’s fascia) that encases the kidney. This stage has substages depending on exactly how far the tumor extends: into the main kidney vein, into the large vein leading to the heart below the diaphragm, or above the diaphragm. T4 means the cancer has broken through that outer envelope or invaded the adrenal gland sitting on top of the kidney.
Staging typically involves a chest CT to check for lung metastases (the most common site of spread), and sometimes a bone scan or brain MRI if symptoms suggest the cancer may have reached those areas. The stage at diagnosis is one of the strongest predictors of outcome and shapes every treatment decision that follows.
Telling Benign Masses From Cancer
Not every kidney mass is malignant. Up to 20% to 30% of small masses removed surgically turn out to be benign. The two most common benign kidney tumors are angiomyolipomas and oncocytomas. Angiomyolipomas often contain visible fat on CT, which is a strong clue that the mass isn’t cancerous. When fat is clearly present, the diagnosis can be made on imaging alone without a biopsy.
The challenge comes with “fat-poor” angiomyolipomas that lack visible fat, and with oncocytomas, which can look nearly identical to cancerous tumors on standard CT or MRI. Advanced imaging analysis, including texture features like how uniform or varied the tissue appears on scans, can help distinguish them. But in many cases, a definitive answer only comes after a biopsy or after the mass is surgically removed and examined under a microscope. This uncertainty is a major reason why biopsy is increasingly encouraged for small kidney masses, particularly when the results would change whether or how aggressively you’re treated.